Norlase secured £2.6 million from WestHill Capital.

Norlase, a Copenhagen, Denmark-based manufacturer of medical devices for ophthalmic conditions, announced securing a capital raise of £2.6 million ($3.2M).

The money was secured from West Hill Capital.

Norlase, founded in 2015 and led by CEO Oliver Hvidt, developed a laser technology in conjunction with the Danish Technical University (DTU), and considered one of the most significant innovations in the treatment of ophthalmic, aesthetic and dermatological medical conditions in over 25 years.

Existing laser based medical devices have remained largely unchanged for decades, with limited development and modernisation. They tend to be bulky, box-like systems that are costly, inflexible, space consuming and that often breakdown.